Special Issue "Antibody-Based Therapeutics Against COVID-19"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (20 September 2021) | Viewed by 3168
Interests: phage display; yeast display; B cell immortalization; vaccine design by epitope analysis; Fc fragments
Special Issues, Collections and Topics in MDPI journals
An emerging coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease known as COVID-19. To date, SARS-CoV-2 continues to rapidly spread globally and seriously threaten public health. Therapeutic antibodies are shown to be very effective in the treatment of various diseases, including viral infection and immune disorder. Clinical trials with antibody-based drugs for COVID-19 are being performed all over the world. Some of them are quite promising. For example, Bamlanivimab, a neutralizing antibody against SARS-CoV-2, was authorized by the FDA for the treatment of COVID-19 in high-risk patients on November 9, 2020. This Special Issue will collect the last progress on antibody-based therapeutics against COVID-19 from bench to bedside.
Prof. Dr. Rui Gong
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- viral infection
- immune disorder